Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 26Prostatic Neoplasms 5Osteosarcoma 5Neuroendocrine Tumors 5Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Sarcoma, Ewing 3Sarcoma 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Medullary 3Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Penile Neoplasms 2Melanoma 2Lung Neoplasms 2Central Nervous System Neoplasms 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Sunitinib 2Everolimus 2sargramostim 1montanide ISA 51 1lutetium Lu 177 dotatate 1lanreotide 1incomplete Freund's adjuvant 1fludarabine phosphate 1cabozantinib 1belzutifan 1X-Rays 1Temozolomide 1Phantoms, Imaging 1Octreotide 1Methods 1Interleukin-13 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Colony-Stimulating Factors 1Blood Specimen Collection 1Biopsy 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × cabozantinib × 90 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡